Paris: Sanofi has announced that the National Medical Products Administration (NMPA) in China has approved Sarclisa, in combination with a standard-of-care regimen, bortezomib, lenalidomide, ...

Study reveals VLCFA metabolism as a key target in multiple myeloma, enhancing drug efficacy and overcoming resistance.

charite.de Objectives To investigate whether bortezomib, a proteasome inhibitor approved for treatment of multiple myeloma, induces clinically relevant plasma cell (PC) depletion in patients with ...

Proteasome inhibitors and stabilizing mutations in the target increase the intensity of the EGFP signal relative to the dsRed signal. Although in-depth characterization of individual proteins by ...

In March 1 Journal of Clinical Investigation Thomas Zollner and colleagues from JW Goethe University of Frankfurt, Germany, show that proteasome inhibition reduces superantigen-mediated T cell ...

China NMPA approves Sanofi’s Sarclisa for patients with newly diagnosed multiple myeloma ineligible for transplant: Paris Saturday, February 1, 2025, 12:00 Hrs [IST] The Nationa ...

Prokaryotic proteasomes are a rare breed: only the Archaea and a few members of the Actinomycetes have been shown to possess a proteasome. But now, this exclusive club has a new member — two ...

The researchers administered mice biotin-epoxomicin, a cell membrane-impermeable proteasome inhibitor that inhibits the activity of neuronal membrane proteasomes to better understand the role of ...

DREAMM-7 is pitting Blenrep against J&J's CD38 drug Darzalex (daratumumab), both in combination with Takeda's proteasome inhibitor Velcade (bortezomib) and dexamethasone, as second-line therapy ...

Paris: Following the adoption of a positive opinion by the European Medicines Agency's (EMA) Committee for Medicinal Products ...